Oxalate (Ox) is a very common component of the human diet, capable of collecting in the renal tissue and binding calcium to form calcium oxalate (CaOx) crystals. Supersaturation of CaOx crystals may cause nephrocalcinosis and nephrolithiasis. The inflammation derived from the CaOx crystal accumulation, together with innate or secondary renal alterations, could strongly affect renal function. In this case, consumption of probiotics with oxalate-degrading activity at the intestinal level and systemic anti-inflammatory activity could be an alternative approach to treat subjects with excess urinary oxalate excretion.
Eleven strains of lactic acid bacteria (Lactobacilli and Bifidobacteria), already included in the list of bacteria safe for human use, were investigated for their capability to degrade oxalate by means of RP-HPLC-UV method and modulate inflammation in an in vitro model system based on peripheral blood mononuclear cells. Four promising bacterial strains (Lactobacillus plantarum PBS067, Lactobacillus acidophilus LA-14, Bifidobacterium breve PBS077, Bifidobacterium longum PBS078) were identified as innovative biological tools for the prevention and therapeutic treatment of hyperoxaluria and the inflammatory events associated with Ox accumulation.